Advertisement

Indian Journal of Surgical Oncology

, Volume 10, Supplement 1, pp 91–98 | Cite as

Hyperthermic Intrathoracic Chemotherapy (HITHOC) for Pleural Malignancies—Experience from Indian Centers

  • Mahesh D. Patel
  • Dileep Damodaran
  • Ashvin Rangole
  • Sakina Shaikh
  • Kairav Shah
  • Rajendra Bagwade
  • Aditi BhattEmail author
Original Article

Abstract

Hyperthermic intrathoracic chemotherapy (HITHOC) has been used in addition to radical surgery for primary and secondary pleural malignancies to improve local control, prolong survival, and improve the quality of life. This study was performed to study the indications, methodology, perioperative outcomes, and survival in patients undergoing HITHOC at Indian centers. A retrospective analysis of prospectively collected demographic and clinical data, perioperative and survival data of patients undergoing surgery with or without HITHOC was performed. From January 2011 to May 2018, seven patients underwent pleurectomy/decortication (P/D) or extrapleural pneumonectomy (EPP) with HITHOC and four had P/D or EPP alone at three Indian centers. P/D was performed in two and EPP in nine patients. The primary tumor was pleural mesothelioma in eight, metastases from thymoma in one, germ cell tumor in one, and solitary fibrous tumor of the pleura in one. HITHOC was performed using cisplatin. Grade 3–4 complications were seen in one patient in the HITHOC group and none in the non-HITHOC group, and one patient in the non-HITHOC group died of complications. At a median follow-up of 9 months, five patients of the HITHOC group were alive, four without recurrence, and one with recurrence. One patient in the non-HITHOC group was alive and disease-free at 24 months, and two died of progression at 18 and 36 months. HITHOC can be performed without increasing the morbidity of P/D or EPP. Most of these patients require multimodality treatment and are best managed by multidisciplinary teams.

Keywords

Pleural mesothelioma HITHOC Pleural metastases 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Ried M, Potzger T, Braune N, Neu R, Zausig Y, Schalke B et al (2013) Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg 43(4):801–807.  https://doi.org/10.1093/ejcts/ezs418 CrossRefGoogle Scholar
  2. 2.
    Shapiro M, Korst RJ (2014) Surgical approaches for stage iva thymic epithelial tumors. Front Oncol 3:332. Published 2014 Jan 14.  https://doi.org/10.3389/fonc.2013.00332 CrossRefGoogle Scholar
  3. 3.
    Migliore M (2017) Debulking surgery and hyperthermic intrathoracic chemotherapy (HITHOC) for lung cancer. Chin J Cancer Res 29(6):533–534CrossRefGoogle Scholar
  4. 4.
    Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83:240–245CrossRefGoogle Scholar
  5. 5.
    DaSilva MC et al (2010) Technique of extrapleural pneumonectomy. Oper Tech Thorac Cardiovasc Surg 15(4):282–293Google Scholar
  6. 6.
    Rusch VW, Niedzwiecki D, Tao Y, Menendez-Botet C, Dnistrian A, Kelsen D, Saltz L, Markman M (1992) Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10:1001–1006CrossRefGoogle Scholar
  7. 7.
    Lerza R, Esposito M, Vannozzi M, Bottino GB, Bogliolo G, Pannacciulli I (1994) High doses of intrapleural cisplatin in a case of malignant pleural mesothelioma. Cancer 73:79–84CrossRefGoogle Scholar
  8. 8.
    United States Department of Public Health and Hu- man Services, NIH, NCI: Common toxicity criteria for adverse events (CTCAE) (2010) National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE_Vers._4.03_2010–06-14;_QuickReference_5x7.pdf. Accessed 31 Oct 2018
  9. 9.
    Tilleman TR, Richards WG, Zellos L, Johnson BE, Jaklitsch MT, Mueller J, Yeap BY, Mujoomdar AA, Ducko CT, Bueno R, Sugarbaker DJ (2009) Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study. J Thorac Cardiovasc Surg 138:405–411CrossRefGoogle Scholar
  10. 10.
    Isik AF, Sanli M, Yilmaz M, Meteroglu F, Dikensoy O, Sevinc A, Camci C, Tuncozgur B, Elbeyli L (2013) Intrapleural hyperthermic perfusion chemotherapy in subjects with metastatic pleural malignancies. Respir Med 107:762–767CrossRefGoogle Scholar
  11. 11.
    van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM (2008) Surgical treatment in the management of malignant pleural mesothelioma: a single institution’s experience. Ann Surg Oncol 15:1757–1764CrossRefGoogle Scholar
  12. 12.
    Sugarbaker PH, Stuart OA, Eger C (2012) Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract 2012:471205Google Scholar
  13. 13.
    Collaud S, de Perrot M (2012) Technical pitfalls and solutions in extrapleural pneumonectomy. Ann Cardiothorac Surg 1(4):537–543Google Scholar
  14. 14.
    Zhao ZY, Zhao SS, Ren M, Liu ZL, Li Z, Yang L (2017) Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget 8(59):100640–100647. Published 2017 Oct 19.  https://doi.org/10.18632/oncotarget.22062 CrossRefGoogle Scholar
  15. 15.
    Ried M, Hofmann HS, Dienemann H, Eichhorn M (2018) Implementation of hyperthermic intrathoracic chemotherapy (hithoc) in Germany. Zentralbl Chir 143(3):301–306.  https://doi.org/10.1055/a-0573-2419 CrossRefGoogle Scholar
  16. 16.
    Liu L, Zhang N, Min J, Su H, Wang H, Chen D, Sun L, Zhang H, Li W, Zhang H (2016) Retrospective analysis on the safety of 5,759 times of bedside hyperthermic intra-peritoneal or intra-pleural chemotherapy (HIPEC). Oncotarget 7:21570–21578.  https://doi.org/10.18632/oncotarget.7622 Google Scholar
  17. 17.
    Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD (2014) A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 83(2):240–245.  https://doi.org/10.1016/j.lungcan.2013.11.026 CrossRefGoogle Scholar
  18. 18.
    Rao S (2009) Malignant pleural mesothelioma. Lung India 26(2):53–54CrossRefGoogle Scholar
  19. 19.
    Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, Bueno R, Richards WG (2013) Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg 145:955–963CrossRefGoogle Scholar
  20. 20.
    Ried M, Potzger T, Sziklavari Z, Diez C, Neu R, Schalke B et al (2013) Extended surgical resections of advanced thymoma Masaoka stages III and IVa facilitate outcome. Thorac Cardiovasc Surg.  https://doi.org/10.1055/s-0033-1345303
  21. 21.
    Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, Lardinois D, Betticher D, Schmid R, Stupp R, Ris H, Jermann M, Mingrone W, Roth A, Spiliopoulos A, On behalf of the Swiss Group for Clinical Cancer Research (2007) Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 18:1196–1202CrossRefGoogle Scholar
  22. 22.
    Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK, Vogelzang NJ (2009) Multicenter phase II trial of neoadjuvant pemetrexed lus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27:3007–3013CrossRefGoogle Scholar
  23. 23.
    Nakas A, Black E, Entwisle J, Muller S, Waller DA (2010) Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg 37:1457–1463CrossRefGoogle Scholar
  24. 24.
    Belcher E, Hardwick T, Lal R, Marshall S, Spicer J, Lang-Lazdunski L (2011) Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interact Cardiovasc Thorac Surg 12(5):744–747.  https://doi.org/10.1510/icvts.2010.255307 CrossRefGoogle Scholar
  25. 25.
    Yellin A, Simansky DA, Ben-Avi R, Perelman M, Zeitlin N, Refaely Y et al (2013) Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience. J Thorac Cardiovasc Surg 145(1):83–87 discussion 87–9.  https://doi.org/10.1016/j.jtcvs.2012.10.013 CrossRefGoogle Scholar
  26. 26.
    Zhou H, Wu W, Tang X, Zhou J, Shen Y (2017) Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: a systematic review and meta-analysis. Medicine (Baltimore) 96(1):e5532CrossRefGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyZydus HospitalAhmedabadIndia
  2. 2.Department of Surgical OncologyMVR Cancer Centre and Research InstituteCalicutIndia
  3. 3.Department of Surgical OncologyCHL, CBCC Cancer CentreIndoreIndia
  4. 4.Department of AnaesthesiologyZydus HospitalAhmedabadIndia

Personalised recommendations